Long-term lamivudine treatment achieves regression of advanced liver fibrosis/cirrhosis in patients with chronic hepatitis B

Journal of Gastroenterology and Hepatology (Australia)

Volumn 30, Issue 2, 2015, Pages 372-378

  Xu, Bei ^a   Lin, Lanyi ^a   Xu, Guoguang ^b   Zhuang, Yan ^a   Guo, Qing ^a   Liu, Yunye ^a   Wang, Hui ^a   Zhou, Xiaqiu ^a   Wu, Shanming ^b   Bao, Shisan ^c   Cai, Wei ^a   Xie, Qing ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

CHB; Cirrhosis; Histopathology improvement; Lamivudine; Regression

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; ANTIVIRUS AGENT; BIOLOGICAL MARKER;

ADD ON THERAPY; ADULT; ADVANCED LIVER FIBROSIS CIRRHOSIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHILD PUGH SCORE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG EFFICACY; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; KIDNEY FAILURE; LEUKOCYTE COUNT; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LONG TERM CARE; MALE; PERITONITIS; PRIORITY JOURNAL; SEROCONVERSION; THROMBOCYTE COUNT; BIOPSY; BLOOD; COMPLICATION; HEPATITIS B, CHRONIC; LIVER; MIDDLE AGED; PATHOLOGY; SEVERITY OF ILLNESS INDEX; TIME FACTOR;

ADULT; ANTIVIRAL AGENTS; BIOMARKERS; BIOPSY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84921525569     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12718     Document Type: Article

References (26)

1. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-539.
2. Lee WM. Hepatitis B virus infection. N. Engl. J. Med. 1997; 337: 1733-1745.
3. Maddrey WC. Hepatitis B: an important public health issue. J. Med. Virol. 2000; 61: 362-366.
4. Koklu S, Tuna Y, Gulsen MT etal. Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis. Clin. Gastroenterol. Hepatol. 2013; 11: 88-94.
5. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003; 362: 2095-2100.
6. Hadziyannis SJ, Papatheodoridis GV. Emerging treatments in chronic hepatitis B. Expert. Opin. Emerg. Drugs 2004; 9: 207-221.
7. Liaw YF, Sung JJ, Chow WC etal. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 2004; 351: 1521-1531.
8. Lai CL, Gane E, Liaw YF etal. Telbivudine versus lamivudine in patients with chronic hepatitis B. N. Engl. J. Med. 2007; 357: 2576-2588.
9. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
10. Lai CL, Chien RN, Leung NW etal. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N. Engl. J. Med. 1998; 339: 61-68.
11. Dienstag JL, Schiff ER, Wright TL etal. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 1999; 341: 1256-1263.
12. Lok AS, Lai CL, Leung N etal. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 1714-1722.
13. Fung S, Kwan P, Fabri M etal. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2014; 146: 980-988.
14. Yim HJ, Seo YS, Yoon EL etal. Adding adefovir vs switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): a 2-year follow-up randomized controlled trial. Liver Int. 2013; 33: 244-254.
15. Sokal EM, Kelly DA, Mizerski J etal. Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B. Hepatology 2006; 43: 225-232.
16. Chotiyaputta W, Degertekin B, McKenna BJ, Samala N, Fontana RJ, Lok AS. Characteristics of chronic hepatitis B patients who underwent liver biopsies. J. Viral. Hepat. 2011; 18: 792-803.
17. Chang TT, Liaw YF, Wu SS etal. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886-893.
18. Marcellin P, Gane E, Buti M etal. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381: 468-475.
19. Garg H, Sarin SK, Kumar M, Garg V, Sharma BC, Kumar A. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology 2011; 53: 774-780.
20. Wong VW, Wong GL, Yiu KK etal. Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. J. Hepatol. 2011; 54: 236-242.
21. Wong VW, Chan FK. Regression of cirrhosis with long-term tenofovir treatment. Gastroenterology 2013; 145: 481-482.
22. Potthoff A, Tillmann HL, Bara C etal. Improved outcome of chronic hepatitis B after heart transplantation by long-term antiviral therapy. J. Viral. Hepat. 2006; 13: 734-741.
23. Kobashi H, Miyake Y, Ikeda F etal. Long-term outcome and hepatocellular carcinoma development in chronic hepatitis B or cirrhosis patients after nucleoside analog treatment with entecavir or lamivudine. Hepatol. Res. 2011; 41: 405-416.
24. Hyun JJ, Seo YS, Yoon E etal. Comparison of the efficacies of lamivudine versus entecavir in patients with hepatitis B virus-related decompensated cirrhosis. Liver Int. 2012; 32: 656-664.
25. Kurokawa M, Hiramatsu N, Oze T etal. Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection. J. Gastroenterol. 2012; 47: 577-585.
26. Chang TT, Lai CL, Kew Yoon S etal. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51: 422-430.